AbbVie

AbbVie operates a research‑driven biopharmaceutical model. It invests heavily in drug discovery and clinical development to build proprietary portfolios in immunology, oncology and other therapeutic areas, then secures regulatory approvals and intellectual property protection to commercialise these medicines globally. Manufacturing is centralised and scaled for biologics and small‑molecule drugs, which are distributed via wholesalers, hospitals, specialty pharmacies and clinics.

Value is created by addressing chronic and severe diseases with targeted therapies, supported by clinical evidence, lifecycle label expansions and payer negotiations. AbbVie enhances its portfolio and pipeline through strategic acquisitions and licensing, such as buying Allergan to add aesthetics and eye‑care brands and acquiring ImmunoGen to obtain an antibody‑drug conjugate platform and approved oncology products. Revenue risk is managed via diversification across multiple drugs, indications and geographies, as well as patient support and access programmes that facilitate treatment continuity and prescriber loyalty.

AbbVie is a US‑based global biopharmaceutical company created in 2013 via separation from Abbott’s research‑based pharmaceuticals business. It discovers, develops, manufactures and commercialises prescription medicines, with major franchises in immunology, dermatology, gastroenterology and oncology, and has expanded into aesthetics and eye care through acquisitions such as Allergan.

The company generates revenue primarily from worldwide sales of branded prescription drugs and biologics through wholesalers, hospitals, specialty pharmacies and other healthcare channels. Its direct paying customers are healthcare providers, distributors and payers, while end‑patients consume the therapies. AbbVie supplements organic R&D with acquisitions of targeted platforms and products, for example antibody‑drug conjugate oncology assets, and operates patient assistance programmes to support access and uptake.